| DIRECT COMPETITOR COMPARISON | |
| ANDS | DVAX | GILD | HGSI | Industry | | Market Cap: | 85.44M | 52.84M | 41.90B | 4.47B | 100.26M | | Employees: | 30 | 155 | 3,441 | 880 | 68 | | Qtrly Rev Growth (yoy): | N/A | -67.20% | 31.40% | 61.30% | 19.70% | | Revenue (ttm): | N/A | 50.07M | 6.41B | 235.70M | 14.01M | | Gross Margin (ttm): | N/A | 43.14% | 77.47% | 10.36% | 65.67% | | EBITDA (ttm): | -28.52M | 1.29M | 3.35B | -8.22M | -12.30M | | Oper Margins (ttm): | N/A | -3.21% | 50.19% | -12.73% | -149.46% | | Net Income (ttm): | -31.54M | 2.80M | 2.43B | -22.51M | N/A | | EPS (ttm): | -0.997 | 0.070 | 2.586 | -0.160 | -0.33 | | P/E (ttm): | N/A | 18.29 | 18.00 | N/A | 16.37 | | PEG (5 yr expected): | N/A | N/A | 1.13 | 186.4 | 1.31 | | P/S (ttm): | N/A | 1.06 | 6.54 | 18.98 | 9.35 |
|
| DVAX = Dynavax Technologies Corporation | | GILD = Gilead Sciences Inc. | | HGSI = Human Genome Sciences Inc. | | Industry = Biotechnology | |
| BIOTECHNOLOGY COMPANIES RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Amgen Inc. | AMGN | 56.50 | 0.00% | 57.19B | 12.32 | | Genentech, Inc. | Private - View Profile | | Biogen Idec Inc. | BIIB | 46.92 | 0.00% | 13.57B | 15.70 | | Genzyme Corp. | GENZ | 51.07 | 0.00% | 13.55B | 29.12 | | Merck Serono S.A. | Private - View Profile | | Chiron Corporation | Private - View Profile | | Gilead Sciences Inc. | GILD | 46.56 | 0.00% | 41.90B | 18.00 | | MedImmune, Inc. | Private - View Profile | | Life Technologies Corporation | LIFE | 49.95 | 0.00% | 8.91B | 1019.39 | | Teva Pharmaceutical Industries Limited | TEVA | 52.88 | 0.00% | 46.59B | 48.38 |
|
| GENERIC DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Sandoz International GmbH | Private - View Profile | | Watson Pharmaceuticals Inc. | WPI | 36.96 | 0.00% | 3.92B | 19.05 | | Barr Pharmaceuticals, Inc. | Private - View Profile | | King Pharmaceuticals Inc. | KG | 11.95 | 0.00% | 2.97B | N/A | | Ranbaxy Laboratories Limited | Private - View Profile | | Mylan, Inc. | MYL | 18.01 | 0.00% | 5.50B | 110.49 | | Pfizer Inc. | PFE | 18.25 | 0.00% | 147.27B | 15.16 | | Johnson & Johnson | JNJ | 62.89 | 0.00% | 173.52B | 13.73 | | GlaxoSmithKline plc | GSK | 42.26 | 0.00% | 107.13B | 13.42 | | Sanofi-Aventis | SNY | 38.43 | 0.00% | 100.35B | N/A |
|
| DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Novartis AG | NVS | 55.38 | 0.00% | 125.78B | 16.58 | | RHHBY.PK | 41.46 | 0.00% | N/A | N/A | | AstraZeneca plc | AZN | 45.29 | 0.00% | 65.67B | 9.09 | | Abbott Laboratories | ABT | 54.08 | 0.00% | 83.65B | 14.65 | | Bristol-Myers Squibb Co. | BMY | 25.38 | 0.00% | 50.28B | 13.13 |
|
| NEWS ON DIRECT COMPETITORS | |
| • | GILD | | A Mostly Meaningless FDA Approval
Fri, Nov 27 -
at Motley Fool | | • | GILD | | 7 of the Most Efficient Companies on the Planet
Fri, Nov 27 -
at Motley Fool | | • | GILD | | Buy These Stocks and Make Money
Fri, Nov 27 -
at Motley Fool | | • | GILD | | [video] Top Stock for 2010
Fri, Nov 27 -
at TheStreet.com | | • | HGSI | | [$$] This Isn't 2003
Fri, Nov 27 -
at RealMoney by TheStreet.com | | • | GILD | | China's B2B Behemoth
Fri, Nov 27 -
at Forbes.com | | • | HGSI | | Human Genome Sciences seeks approval for Zalbin
Wed, Nov 25 -
AP | | • | HGSI | | Human Genome Sciences Submits Biologics License Application to FDA for ZALBIN
Wed, Nov 25 -
Business Wire | | • | HGSI | | Best Performing U.S. Stocks Year to Date
Tue, Nov 24 -
at Seeking Alpha | | • | HGSI | | Signals Favor a Santa Claus Rally
Tue, Nov 24 -
at Minyanville.com | | • | HGSI | | Wall Street's Buy List
Tue, Nov 24 -
at Motley Fool | | • | DVAX | | DYNAVAX TECHNOLOGIES CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Thu, Nov 19 -
EDGAR Online | | • | DVAX | | DVAX Completes Hep-B Enrollment
Thu, Nov 19 -
Zacks.com | | • | DVAX | | Dynavax Completes Enrollment of First Cohort of Patients in Phase 1b Clinical Trial for Hepatitis B Therapy
Thu, Nov 19 -
Marketwire | | • | DVAX | | Big Pullback for Top Swine Flu Small-Caps
Tue, Nov 17 -
Indie Research | | • | DVAX | | DYNAVAX TECHNOLOGIES CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Ex
Tue, Nov 10 -
EDGAR Online | | • | DVAX | | Dynavax Technologies to buy Symphony Dynamo
Tue, Nov 10 -
at bizjournals.com | | | All Headlines for these symbols... |
|
|
|
1.48% Nasdaq 0.00%
Competitors
